Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...

One of these medicines, Eylea, also blocks another substance called placental growth factor (PlGF) and may be an option for people with wet AMD. As you age, you may develop a condition that causes ...

Eylea (aflibercept) is a biologic drug prescribed to help prevent vision loss in certain situations. It’s a liquid solution given by healthcare professionals as an injection into the eye. Eylea ...

Eylea and Eylea HD (aflibercept) are prescription drugs used to treat certain types of eye conditions. Each comes as a liquid solution given as an injection into the eye. The dosing schedules can ...

Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

With U.S. sales of $304 million during the second quarter, Regeneron’s high-dose version of Eylea came up just short of analyst projections. But it was a significant increase from the $200 ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...